Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × HCC × nimotuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 7 Esophageal Neoplasms 4 Pancreatic Neoplasms 3 Esophageal Squamous Cell Carcinoma 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Pancreatic Cancer Resectable 1 Neoplasm Metastasis 1 Head and Neck Neoplasms 1 HCC 1

Interventions

nimotuzumab 1 atezolizumab 1 Tirapazamine 1 Radiotherapy 1 Radiosurgery 1 Immune Checkpoint Inhibitors 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06413017 2024-05-14

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡